At DICE Therapeutics, we are developing selective oral small molecules that have the potential to treat chronic diseases in immunology and other therapeutic areas. We utilize our DELSCAPE platform to generate small molecule antagonists against a range of validated protein-protein-interface (PPI) targets. We believe there is a significant unmet medical need for convenient oral therapies that offer the therapeutic benefits of systemic biologics.